logo-loader
Poolbeg Pharma PLC

Poolbeg Pharma PLC - European patent granted for POLB 001 in CRS

RNS Number : 3838I
Poolbeg Pharma PLC
16 June 2026
 

A blue and white logo AI-generated content may be incorrect.

 

Poolbeg Pharma plc

 

Decision to grant European Patent received for POLB 001 in cancer immunotherapy-induced CRS

 

Major milestone will provide IP protection in key European markets, strengthening global patent portfolio

 

16 June 2026 - Poolbeg Pharma (AIM: POLB, 'Poolbeg' or the 'Company'), a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field, announces that it has received formal notification of the decision to grant for its POLB 001 cancer immunotherapy-induced Cytokine Release Syndrome ("CRS") patent application from the European Patent Office ("EPO").

 

This represents a significant milestone for the Company's global intellectual property strategy. The European patent, which provides protection across EPO member states, is the most commercially significant grant to date within Poolbeg's cancer immunotherapy-induced CRS patent family, covering one of the world's largest and most important pharmaceutical markets. This follows the grant of the first patent in this family by IP Australia in March 2026, followed by patent grant in Canada in May 2026 and further reinforces the Company's commitment to building a robust, worldwide IP portfolio.

 

The patent covers the use of p38 MAPK inhibitors, including POLB 001, for the prevention of cancer immunotherapy-induced CRS, supported by proprietary data generated by the Company. The grant materially strengthens Poolbeg's competitive position as it advances POLB 001 through the clinic. With the TOPICAL trial on track to deliver interim data later this summer, the Company believes this milestone significantly enhances POLB 001's attractiveness to potential partners and its long-term value proposition. The Company looks forward to providing further updates to the market regarding the extension of coverage in other jurisdictions in due course.

 

Jeremy Skillington, PhD, Chief Executive Officer of Poolbeg Pharma, said: "This decision to grant the European patent further strengthens our IP protection for POLB 001 in cancer immunotherapy-induced CRS. Europe represents one of the most strategically important pharmaceutical markets and this grant increases the commercial value of POLB 001 to potential partners at a critical stage in the programme's development. With interim data from our TOPICAL trial expected this summer and our IP portfolio further bolstered, I am excited by what is to come over the months ahead for Poolbeg."

 

*TOPICAL: Trial of Prevention of ImmunoCytokine Adverse events in Myeloma. A single-arm, open-label trial investigating POLB 001 as a potential preventative for CRS in relapsed/refractory multiple myeloma patients receiving the approved bispecific antibody, teclistamab, provided by Johnson and Johnson at no cost to Poolbeg.

 

Enquiries

 

Poolbeg Pharma Plc

Jeremy Skillington, CEO

Ian O'Connell, CFO

 

+44 (0) 207 183 1499

ir@poolbegpharma.com

Cavendish Capital Markets Ltd (NOMAD & Joint Broker)

Geoff Nash, Trisyia Jamaludin (Corporate Finance)

Nigel Birks (Life Science Specialist Sales)

Harriet Ward (ECM)

 

+44 (0) 207 220 0500

Shore Capital Stockbrokers Ltd (Joint Broker)

David Coaten, Harry Davies-Ball (Corporate Advisory)
Malachy McEntyre (Corporate Broking)

+44 (0) 207 408 4090

J&E Davy (Joint Broker)

Anthony Farrell, Niall Gilchrist

 

+353 (0) 1 679 6363

Optimum Strategic Communications

Nick Bastin, Katie Flint, Elena Bates

 

+44 (0) 208 078 4357

poolbeg@optimumcomms.com

 

About Poolbeg Pharma plc 

Poolbeg Pharma plc (AIM: POLB) is a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field. The Company's lead asset, POLB 001, has the potential to expand administration of cancer immunotherapies from centralised specialist cancer centres into community hospitals by making the treatments safer through the prevention of the life-threatening side effect, Cytokine Release Syndrome (CRS). As such, POLB 001 could increase the number of patients that can receive these life-saving treatments, thereby increasing the market opportunity. Poolbeg is also advancing the development of a patient-friendly therapy for obesity with an oral encapsulated GLP-1, offering a differentiated approach within one of the world's largest markets. With multiple near-term clinical value inflection points, and an experienced team with a proven track record, Poolbeg is focussed on partnering its high value programmes that are targeting large markets and addressing critical unmet medical needs. 

 

Stay updated: Website | Sign up for RNS alerts | Presentation | X | LinkedIn

 

Forward-Looking Statements

This announcement may contain forward-looking statements and the words "expect", "anticipate", "intends", "plan", "estimate", "aim", "forecast", "project" and similar expressions (or their negative) identify certain of these forward-looking statements. The forward-looking statements in this announcement are based on numerous assumptions and Poolbeg's present and future business strategies and the environment in which Poolbeg expects to operate in the future. Forward-looking statements involve inherent known and unknown risks, uncertainties and contingencies because they relate to events and depend on circumstances that may or may not occur in the future and may cause the actual results, performance or achievements to be materially different from those expressed or implied by such forward-looking statements. These statements are not guarantees of future performance or the ability to identify and consummate investments. Many of these risks and uncertainties relate to factors that are beyond Poolbeg's ability to control or estimate precisely, such as future market conditions, currency fluctuations, the behaviour of other market participants, the outcome of clinical trials, the actions of regulators and other factors such as Poolbeg's ability to obtain financing, changes in the political, social and regulatory framework in which Poolbeg operates or in economic, technological or consumer trends or conditions. Past performance should not be taken as an indication or guarantee of future results, and no representation or warranty, express or implied, is made regarding future performance. No person is under any obligation to update or keep current the information contained in this announcement or to provide the recipient of it with access to any additional relevant information.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCUVARRNVUNAUR
NO INVESTMENT ADVICE

Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.

Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.

This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.

In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.

The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.

Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

FOR OUR FULL DISCLAIMER CLICK HERE

Gelion, Bango, Poolbeg Pharma, Georgina Energy, Kenmare Resources - Small...

Gelion PLC (AIM:GELN, OTC:GELNF, FRA:X0S) has secured an evaluation deal with a top-15 global automaker for its sulfur battery cathode tech. It's now working with several major OEMs on EV applications. Read more  Bango PLC (AIM:BGO, OTCQX:BGOPF) has been selected by South Korean telecoms...

on 10/06/2026

5 min read